Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine

Neoplasia

Volumn 6, Issue 5, 2004, Pages 569-577

  Yao, Ruisheng ^a   Lemon, William J ^a   Wang, Yian ^a   Grubbs, Clinton J ^b   Lubet, Ronald A ^c   You, Ming ^a  

^a USA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Affymetrix microarray; Differential expression; Expression profile; Mouse bladder cancer; Signaling pathway

Indexed keywords

CARCINOGEN; HYDROXYBUTYL(BUTYL)NITROSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NITROSAMINE; OLIGONUCLEOTIDE; PROTEIN SH2; RAB PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; STAT1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; INTRACELLULAR TRANSPORT; MALE; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 6944225349     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04223     Document Type: Article

References (50)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, and Thun MJ (2003). Cancer Statistics, 2003. CA Cancer J Clin 53, 5-26.
2. Czerniak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F, and Koss LG (1992). Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol 23, 1199-1204.
3. Olderoy G, Daehlin L, and Ogreid D (1998). Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res 18, 2675-2678.
4. Buyru N, Tigli H, Ozcan F, and Dalay N (2003). Ras oncogene mutations in urine sediments of patients with bladder cancer. J Biochem Mol Biol 36, 399-402.
5. Knowles MA (1995). Molecular genetics of bladder cancer. Br J Urol 1, 57-66.
6. Shinohara N and Koyanagi T (2002). Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment? Urol Res 30, 273-281.
7. Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, and Schulz WA (2003). Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 282, 48-57.
8. Brandau S and Bohle A (2001). Bladder cancer: I. Molecular and genetic basis of carcinogenesis. Eur Urol 39, 491-497.
9. Orntoft TF and Wolf H (1998). Molecular alterations in bladder cancer. Urol Res 26, 223-233.
10. Knowles MA (1999). The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 84, 412-427.
11. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, and Seibert K (2000). Celecoxib inhibits N-butyl-N-(4-hydroxybutyl) -nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60, 5599-5602.
12. Grubbs CJ, Moon RC, Squire RA, Farrow GM, Stinson SF, Goodman DG, Brown CC, and Sporn MB (1977). 13-cis-Retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Science 198, 743-744.
13. Ogawa K, Uzvolgyi E, St John MK, de Oliveira ML, Arnold L, and Cohen SM (1998). Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice. Mol Carcinog 21, 70-79.
14. Yamamoto S, Chen T, Murai T, Mori S, Morimura K, Oohara T, Makino S, Tatematsu M, Wanibuchi H, and Fukushima S (1997). Genetic instability and p53 mutations in metastatic foci of mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 18, 1877-1882.
15. Gao J, Huang HY, Pak J, Cheng J, Zhang ZT, Shapiro E, Pellicer A, Sun TT, and Wu XR (2004). p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 23, 687-696.
16. Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, and Wu XR (2001). Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20, 1973-1980.
17. el-Marjou A, Delouvee A, Thiery JP, and Radvanyi F (2000). Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. Carcinogenesis 21, 2211-2218.
18. Yao R, Wang Y, Lubet RA, and You M (2002). Differentially expressed genes associated with mouse lung tumor progression. Oncogene 21, 5814-5821.
19. Eisen MB, Spellman PT, Brown PO, and Botstein D (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95, 14863-14868.
20. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, and Conklin BR (2002). GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 31, 19-20.
21. Kroft SH and Oyasu R (1994). Urinary bladder cancer: mechanisms of development and progression. Lab Invest 71, 158-174.
22. Theodorescu D, Cornil I, Fernandez BJ, and Kerbel RS (1990). Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci USA 87, 9047-9051.
23. Vageli D, Kiaris H, Delakas D, Anezinis P, Cranidis A, and Spandidos DA (1996). Transcriptional activation of H-ras, K-ras and N-ras protooncogenes in human bladder tumors. Cancer Lett 107, 241-247.
24. Cherfils J and Chardin P (1999). GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem Sci 24, 306-311.
25. Theodorescu D, Cornil I, Sheehan C, Man MS, and Kerbel RS (1991). Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res 51, 4486-4491.
26. Sahai E and Marshall CJ (2002). RHO-GTPases and cancer. Nat Rev Cancer 2, 133-142.
27. Zheng Y (2001). DbI family guanine nucleotide exchange factors. Trends Biochem Sci 26, 724-732.
28. Moon SY and Zheng Y (2003). Rho GTPase-activating proteins in cell regulation. Trends Cell Biol 13, 13-22.
29. Seraj MJ, Harding MA, Gildea JJ, Welch DR, and Theodorescu D (2000). The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 18, 519-525.
30. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, and Theodorescu D (2002). RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62, 6418-6423.
31. Joneson T and Bar-Sagi D (1999). Suppression of Ras-induced apoptosis by the Rac GTPase. Mol Cell Biol 19, 5892-5901.
32. Malumbres M and Barbacid M (2001). To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1, 222-231.
33. Morgan DO (1995). Principles of CDK regulation. Nature 374, 131-134.
34. Peters JM (2002). The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 9, 931-943.
35. Nigg EA (2001). Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2, 21-32.
36. Morris MC, Kaiser P, Rudyak S, Baskerville C, Watson MH, and Reed SI (2003). Cks1-dependent proteasome recruitment and activation of CDC20 transcription in budding yeast. Nature 424, 1009-1013.
37. Paggi MG, Baldi A, Bonetto F, and Giordano A (1996). Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 62, 418-430.
38. Paggi MG and Giordano A (2001). Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother. Cancer Res 61, 4651-4654.
39. Qian YW and Lee EY (1995). Dual retinoblastoma-binding proteins with properties related to a negative regulator of ras in yeast. J Biol Chem 270, 25507-25513.
40. Nicolas E, Ait-Si-Ali S, and Trouche D (2001). The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein. Nucleic Acids Res 29, 3131-3136.
41. Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, and Dean DC (2000). Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 101, 79-89.
42. Chen GC, Guan LS, Yu JH, Li GC, Choi Kim HR, and Wang ZY (2001). Rb-associated protein 46 (RbAp46) inhibits transcriptional transactivation mediated by BRCA1. Biochem Biophys Res Commun 284, 507-514.
43. Guan LS, Li GC, Chen CC, Liu LQ, and Wang ZY (2001). Rb-associated protein 46 (RbAp46) suppresses the tumorigenicity of adenovirus-transformed human embryonic kidney 293 cells. Int J Cancer 93, 333-338.
44. Neves SR, Ram PT, and Iyengar R (2002). G protein pathways. Science 296, 1636-1639.
45. Massague J, Blain SW, and Lo RS (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309.
46. Siegel PM, Shu W, Cardiff RD, Muller WJ, and Massague J (2003). Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100, 8430-8435.
47. Derynck R, Akhurst RJ, and Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29, 117-129.
48. Yan S, Krebs S, Leister KJ, and Wenner CE (2000). Perturbation of EGF-activated MEK1 and PKB signal pathways by TGF-beta1 correlates with perturbation of EGF-induced cyclin D1 and DNA synthesis by TGF beta1 in C3H 10T1/2 cells. J Cell Physiol 185, 107-116.
49. Bakin AV, Rinehart C, Tomlinson AK, and Arteaga CL (2002). p38 mitogen activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115, 3193-3206.
50. Edlund S, Landstrom M, Heldin CH, and Aspenstrom P (2002). Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 13, 902-914.